Neurodegenerative Disorders

GSKs newest neuro pact is with ABL Bio, a Sanofi-partnered South Korean biotech

2 weeks ago talkbio0Tagged Abetalipoproteinemia, Bio, Blood - brain barrier anatomy, Grabody-B, IGF1R gene, Neurodegenerative Disorders, SmithKline Beecham

Abetalipoproteinemia, SmithKline Beecham, Bio, Grabody-B, Neurodegenerative Disorders, Blood – brain barrier anatomy, IGF1R gene

TRIMTECH Therapeutics raises $31M seed funding to advance targeted protein degradation pipeline for treatment of neurodegenerative diseases

2 months ago talkbio0Tagged cellular targeting, Clinical Nurse Specialists, degraders, Neurodegenerative Disorders, Plant seeds, Protein Degradation, Metabolic, TRIM21, TRIMTAC

targeted protein degradation, neurodegenerative diseases, TRIM21, TRIMTAC degraders, CNS therapeutics, seed funding, biotech startup

GE HealthCare and UCSF Launch ‘Care Innovation Hub’ to Revolutionize Medical Imaging for Cancer and Neurodegenerative Diseases

3 months ago talkbio0Tagged Automated (qualifier value), brain health, ELAVL2 gene, GE HealthCare, innovation, Magnetic Resonance Imaging, Medical Imaging, Neoplasms, Neurodegenerative Disorders, Precision - temporal, radiopharmaceutical therapies, UCSF

GE HealthCare, UCSF, Care Innovation Hub, medical imaging, cancer, neurodegenerative diseases, precision oncology, brain health, automated imaging techniques, MRI, radiopharmaceutical therapies.

Eli Lilly and Alchemab Therapeutics Collaborate on Novel ALS Therapies

3 months ago talkbio0Tagged Alchemab, Amyotrophic Lateral Sclerosis, Drug Development, Eli, Eli Lilly, Neurodegenerative Disorders, Therapeutic Antibodies

Eli Lilly, Alchemab Therapeutics, ALS, Therapeutic Antibodies, Neurodegenerative Disease, Drug Development

Denali Therapeutics’ ALS Drug DNL343 Fails to Meet Primary Efficacy Endpoints in Phase 2/3 HEALEY ALS Platform Trial

3 months ago talkbio0Tagged Agonist, Amyotrophic Lateral Sclerosis, Clinical trial failure, Denali, DNL343, Eukaryotic Initiation Factor-2B, HEALEY, Neurodegenerative Disorders

Denali Therapeutics, DNL343, ALS (Amyotrophic Lateral Sclerosis), HEALEY ALS Platform Trial, eIF2B agonist, Clinical trial failure, Neurodegenerative diseases

GSK Partners with Muna Therapeutics to Unlock Novel Alzheimer’s Treatments

5 months ago talkbio0Tagged Alzheimer 's disease, Drug Discovery, MiND-MAP platform, Muna, Neurodegenerative Disorders, SmithKline Beecham, spatial transcriptomics, targets

Muna Therapeutics, GSK, Alzheimer’s disease, neurodegenerative diseases, spatial transcriptomics, MiND-MAP platform, drug discovery, therapeutic targets.